Ekso Bionics (NASDAQ:EKSO) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Ekso Bionics (NASDAQ:EKSO) announced its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07), Zacks reports. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%.

Ekso Bionics Trading Down 8.1 %

EKSO traded down $0.04 during trading on Monday, reaching $0.48. 226,205 shares of the company’s stock were exchanged, compared to its average volume of 348,919. The company’s fifty day moving average price is $0.61 and its 200-day moving average price is $0.83. The firm has a market capitalization of $10.61 million, a PE ratio of -0.74 and a beta of 1.46. Ekso Bionics has a fifty-two week low of $0.47 and a fifty-two week high of $2.16. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Analyst Upgrades and Downgrades

EKSO has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, January 14th. StockNews.com initiated coverage on shares of Ekso Bionics in a report on Monday. They set a “hold” rating on the stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.